As we kept describing it, Illumina’s (ILMN) is the engine behind the biological revolution reflected in the current existence of treatments, which aim at targets that were unknown before this firm enabled discovering them.
Illumina’s establishing and launching the independent company, Grail, will speed the successful outcome of the war against cancer. It will contribute to advancing the diagnosis of cancer through a tremendous increase in the sensitivity of DNA sequencing technology. Grail will be using Illumina’s advanced sequencing technologies to detect the tiniest pieces of DNA shed by cancerous tumors . . .